Loading clinical trials...
Loading clinical trials...
Phase II Prospective Study to Assess Rate for Prolonged Remission With Intensive Chemotherapy in Rapid Respondents AML Patients Younger Than 61 as Demonstrated by Day 5 Examination of the First Treatment.
Conditions
Interventions
Prescribing conventional chemotherapy while with holding allo-SCT
Start Date
April 15, 2019
Primary Completion Date
November 1, 2021
Completion Date
November 1, 2023
Last Updated
April 8, 2019
NCT06285890
NCT06220162
NCT04065399
NCT06994676
NCT06484062
NCT04628026
Lead Sponsor
Rambam Health Care Campus
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions